Trevena, Inc. (TRVN)
NASDAQ: TRVN · IEX Real-Time Price · USD
0.460
+0.001 (0.31%)
At close: Mar 28, 2024, 4:00 PM
0.456
-0.004 (-0.89%)
After-hours: Mar 28, 2024, 7:53 PM EDT
Company Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
Trevena, Inc.
Country | United States |
Founded | 2007 |
IPO Date | Jan 31, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 35 |
CEO | Ms. Carrie L. Bourdow |
Contact Details
Address: 955 Chesterbrook Boulevard, Suite 110 Chesterbrook, Pennsylvania 19087 United States | |
Phone | (610) 354-8840 |
Website | trevena.com |
Stock Details
Ticker Symbol | TRVN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001429560 |
CUSIP Number | 89532E109 |
ISIN Number | US89532E2081 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Carrie L. Bourdow | President, Chief Executive Officer and Chairman |
Barry Shin | Executive Vice President, Chief Operating Officer and Chief Financial Officer |
Dr. Mark A. Demitrack M.D. | Senior Vice President and Chief Medical Officer |
Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board |
Joel Solomon | Vice President, General Counsel and Chief Compliance Officer |
Michael Catalano | Vice President of Marketing |
Robert T. Yoder | Senior Vice President, Chief Business Officer and Head of Commercial Operations |
Patricia M. Drake | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Mar 21, 2024 | 8-K | Current Report |
Mar 6, 2024 | 8-K | Current Report |
Feb 20, 2024 | DEF 14A | Other definitive proxy statements |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 9, 2024 | PRE 14A | Other preliminary proxy statements |
Feb 1, 2024 | 8-K | Current Report |
Jan 23, 2024 | 424B3 | Prospectus |
Jan 22, 2024 | EFFECT | Notice of Effectiveness |
Jan 19, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |